Cytoskeletal protein

Cytoskeletal proteins constitute a dynamic and complex framework of filaments—categorized into microtubules, microfilaments (actin), and intermediate filaments—that provide the essential structural architecture and mechanical integrity of eukaryotic cells [5, 12]. Beyond providing physical support, these proteins are integral to a vast array of biological processes, including the regulation of cell shape, intracellular organelle transport, signal transduction, and the orchestration of chromosomal segregation during mitosis [6, 11]. In many disease states, particularly cancer, the cytoskeletal network is reprogrammed to support the pathological hallmarks of uncontrolled proliferation, increased motility, and tissue invasion [2, 9]. Consequently, several components of the cytoskeleton serve as primary therapeutic targets; for example, microtubule-stabilizing agents like taxanes and tubulin-polymerization inhibitors like vinca alkaloids are foundational in modern oncology [4, 16]. While emerging research investigates targeting actin-associated proteins and intermediate filaments for neurodegenerative and cardiovascular conditions, the high conservation of these proteins across different cell types presents a significant challenge for drug specificity, often leading to dose-limiting toxicities such as peripheral neuropathy [4, 13, 14].

Other names

CytoskeletonCytoskeletal networkCellular scaffoldCytoskeletal filamentsIntracellular scaffoldCellular structural proteins

Drugs targeting the cytoskeletal network primarily function by modulating the assembly and disassembly dynamics of its protein subunits. This is achieved through three major mechanisms: stabilization of existing polymers (e.g., taxanes preventing microtubule depolymerization), inhibition of polymerization (e.g., vinca alkaloids sequestering tubulin dimers or capping filament ends), and the active promotion of polymer disassembly/depolymerization [4, 6, 16].